November 27, 2019
View Full PaperPredictors of Primary Response to Biologic Treatment Anti-TNF, Vedolizumab, and Ustekinumab in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
Key Points
Key points are not available for this paper at this time.
Abstract
In summary, currently no single marker fulfils all criteria for being an appropriate prognostic indicator of response to any biologic treatment in IBD.